Devintec Pharma is a private and independent company based in Lugano. Our business is based on advanced Research & Development that leads to discovering, developing and successively licensing innovative Substance-based Medical Devices (SMD). Our history begins with the creation of Novintethical Pharma SA in 2008 and later Devintec Sagl, created to drive Novintethical’s Global Market access. Our companies sucessfully developed products such as Tasectan®, Xilaplus® and Gelsectan®, for gastrointestinal disorders and Utipro® for the treatment and prevention of urinary tract infections. We apply the unique technology of DevinPro™ to our patented healthcare solutions. This innovative Mechanism of Action, forms a protective mucus-like barrier that avoids the adhesion and proliferation of pathogens and promotes the epithelial integrity, enabling the treatment of multiple diseases, providing clinically-proven, non pharmaceutical solutions with a safety and efficacy profile. Our technology: • Substance-based Medical Devices (SMD) • Non-pharmaceutical compounds with an innovative Mechanism of Action (MoA) • Science-driven combination of substances, enhancing the epithelial barrier integrity and function • Clinically-proven therapies in several disease areas including gastroenterology dermatology, and women’s health • Our patented DevinPro™ technology helps to restore the epithelial barrier integrity and function Therapeutic agents or adjuvant options for the management of challenging medical conditions Devintec Pharma looks for scientifically-driven companies that are looking for innovative substance-based Medical Devices in the following therapeutic areas: Gastroenterology, Dermatology, Gynecology and Allergology